Abstract
Chronic inflammatory diseases, associated with airway obstruction and cough, are usually treated with bronchodilating and anti-inflammatory drugs. Inhibition of phosphodiesterases (PDE) leads to both of these effects and influences apoptosis of immune cells. In chronic obstructive pulmonary disease, roflumilast, a selective PDE4 inhibitor, has been recently approved for pharmacotherapy. The aim of this study was to evaluate the effect of long-term administration of roflumilast in experimental allergic inflammation in guinea pigs. Male adult guinea pigs were used in the study. There were four experimental groups sensitized with ovalbumin for 14 days and thereafter treated per os, by inhalation, and intraperitoneally for 7 days with roflumilast or vehicle. A control group was left without sensitization. Roflumilast reduced specific airway resistance after nebulization of histamine, as measured in a double-chamber whole-body plethysmograph. This effect was confirmed in in vitro organ bath, with significant decreases in tracheal and lung smooth muscle contractility after cumulative doses of histamine. Suppression of hematological and immunological markers of inflammation and enhanced apoptosis in animals treated with roflumilast points to the possibility of a beneficial effect of roflumilast in allergic inflammation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Antoniu SA (2011) New therapeutic options in the management of COPD – focus on roflumilast. Int J Chron Obstruct Pulm Dis 6:147–155
Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol 297:280–290
Champan RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE (2007) Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Eur J Pharmacol 571:215–221
Duncan CJA, Lawrie A, Blaylock MG, Douglas JG, Walsh GM (2003) Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J 22:484–490
Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57:48–64
Hatzelmann A, Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. Pharmacol Exp Ther 297:267–279
Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235–256
Keravis T, Lugnier C (2011) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165:1288–1305
Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, Bardin PB (2007) Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 74:411–417
Maarsingh H, Zaagsma J, Meurs H (2009) Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol 158:652–664
McIvor RA (2008) Roflumilast: systemic therapy for chronic obstructive pulmonary disease. Expert Rev Respir Med 5:539–549
Mokry J, Mokra D, Nosalova G, Beharkova M, Fehierova Z (2008) Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 6:473–482
O’Byrne PM, Inman MD (2003) Airway hyperresponsiveness. Chest 3:411–416
Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163:53–67
Raouf AA (2007) Apoptosis and asthma. Egypt J Bronchol 1:107–119
Robinson DS (2005) The role of regulatory T lymphocytes in asthma pathogenesis. Curr Allergy Asthma Rep 5:136–141
Schalkwyk E, Strydom K, Williams Z, Venter C, Leichtl S, Schmidt-Wirtlitsch C, Bredenbröker D, Bardin PG (2005) Roflumilast, an oral, once daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 116:292–298
Simon HU (2001) Eosinophil apoptosis – pathophysiologic and therapeutic implications. Eur J Allergy Clin Immunol 10:910–915
Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308–315
Tagaya E, Tamaoki J (2007) Mechanisms of airway remodeling in asthma. Allergol Int 56:331–340
Vignola AM (2004) PDE4 inhibitors in COPD – a more selective approach to treatment. Respir Med 98:495–503
Walsh GM (2008) Defective apoptotic cell clearance in asthma and COPD – a new drug target for statin? Trends Pharmacol Sci 29:6–11
Acknowledgments
This work was supported by the Slovak Research and Development Agency under the contract No. APVV-0305-12, by Grant MZ2012/35-UKMA-12, Grant VEGA 1/0030/11, and by project UK/159/2013.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Medvedova, I., Prso, M., Eichlerova, A., Mokra, D., Mikolka, P., Mokry, J. (2014). Influence of Roflumilast on Airway Reactivity and Apoptosis in Ovalbumin-Sensitized Guinea Pigs. In: Pokorski, M. (eds) Allergens and Airway Hyperreactivity. Advances in Experimental Medicine and Biology(), vol 838. Springer, Cham. https://doi.org/10.1007/5584_2014_77
Download citation
DOI: https://doi.org/10.1007/5584_2014_77
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10008-1
Online ISBN: 978-3-319-10009-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)